FilthyPeasant
Oct 3, 10:40 PM
$SLS REGAL success leads to application of GPS across all maintenance settings in AML, with or without SCT, CR1/2/3. The point of the trial's designwas an acid test for the mechanism of action. If GPS can help the immune system of the sickest patient cohort within AML (ie. REGAL's patient population, CR2 & SCT ineligible), then it will confer a similar, or far likely even greater benefit, onto earlier/healthier AML patient populations. Watch out, lots of accounts that will flip-flop their claims for odd reasons but this point you raise is absolutely axiomatic. The company and clinicians have repeatedly discussed how success in REGAL leads to a new SoC in AML maintenance for all patients achieving remission and the use of a SCT does not in anyway preclude efficacy and/or the utility of administering GPS to the same patient.
0 replies
